pre-miRNA Information
pre-miRNA hsa-mir-628   
Genomic Coordinates chr15: 55372940 - 55373034
Synonyms MIRN628, hsa-mir-628, MIR628
Description Homo sapiens miR-628 stem-loop
Comment The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies .
RNA Secondary Structure
Associated Diseases

Mature miRNA Information
Mature miRNA hsa-miR-628-3p
Sequence 61| UCUAGUAAGAGUGGCAGUCGA |81
Evidence Experimental
Experiments Microarray
Editing Events in miRNAs
Modification Type Position on miR Chromosome DNA Strand Genomic Position (hg38) List of PMIDs Variant details
A-to-I 7 15 - 55372968 29233923 MiREDiBase
A-to-I 8 15 - 55372967 29233923 MiREDiBase
C-to-U 19 15 - 55372956 20591823 MiREDiBase
DRVs in miRNA
Mutant ID Mutant Position Mutant Source
COSN26969715 1 COSMIC
COSN30123186 10 COSMIC
SNPs in miRNA
Mutant ID Mutant Position Mutant Source
rs1410255602 2 dbSNP
rs1401315366 3 dbSNP
rs1322836365 4 dbSNP
rs1158103480 8 dbSNP
rs1216611749 11 dbSNP
rs749619551 13 dbSNP
rs778157225 18 dbSNP
rs756600789 19 dbSNP
Putative Targets

miRNA Expression profile
Human miRNA Tissue Atlas
miRNAs in Extracellular Vesicles
Circulating MicroRNA Expression Profiling
Gene Information
Gene Symbol TARBP2   
Synonyms LOQS, TRBP, TRBP1, TRBP2
Description TARBP2, RISC loading complex RNA binding subunit
Transcript NM_004178   
Other Transcripts NM_134323 , NM_134324   
Expression
Putative miRNA Targets on TARBP2
3'UTR of TARBP2
(miRNA target sites are highlighted)
>TARBP2|NM_004178|3'UTR
   1 AGCCCCAGCTGGACTCATGGATGTGCACCCTTTGCTCCCTGCTCTTTCTGCCTCTGGGCTCATGTATCTGCGCAGCTCTG
  81 GTACCCTCTGTGGGTGCCATCTCTACCTCTGACACAGACTGCCTGCCTTGAAGCTGAGAAGGCACAGGGCAAGGAGCCAA
 161 GGACCACAGAGCCTCAGCCAGCCCAGGATCCGTCCTCATTTTATTGGTGATGATGAATGGGAATGAAATCAGGGGGCTGT
 241 CTACTAGAGCCTGGAATAAATATGCTGCTTTGTGGATTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
 321 AAAA
Target sites Provided by authors   Predicted by miRanda    DRVs    SNPs    DRVs & SNPs
miRNA-target interactions
(Predicted by miRanda)
ID Duplex structure Position Score MFE
1
miRNA  3' agCUGACGGUGAGAAUGAUCu 5'
            |:|||:|     |||||| 
Target 5' ggGGCTGTC-----TACTAGa 3'
233 - 248 125.00 -14.60
2
miRNA  3' agCU-GAC-GGUG-AGAAUGAUCu 5'
            || | | || | |:|||:|:| 
Target 5' agGATCCGTCCTCATTTTATTGGt 3'
185 - 208 119.00 -8.70
3
miRNA  3' agCUG-ACGGUGAGAAUGAucu 5'
            ||: |||  | :||:||   
Target 5' tgGATGTGCACCCTTTGCTccc 3'
18 - 39 99.00 -7.32
DRVs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
COSN31554832 3 COSMIC
COSN30473334 6 COSMIC
COSN28876142 22 COSMIC
COSN30177846 24 COSMIC
COSN30524696 39 COSMIC
COSN30506357 40 COSMIC
COSN31540315 98 COSMIC
COSN30187955 110 COSMIC
COSN28812429 209 COSMIC
COSN31483849 242 COSMIC
SNPs in gene 3'UTRs
Mutant ID Mutant Position Mutant Source
rs568796843 2 dbSNP
rs767686359 6 dbSNP
rs750204119 7 dbSNP
rs1303409598 9 dbSNP
rs1380699334 11 dbSNP
rs1423088988 13 dbSNP
rs539489466 18 dbSNP
rs766053638 19 dbSNP
rs753874744 21 dbSNP
rs754908800 22 dbSNP
rs1247635221 23 dbSNP
rs750331078 24 dbSNP
rs764848884 26 dbSNP
rs376072604 27 dbSNP
rs752218932 29 dbSNP
rs758146970 31 dbSNP
rs1482312106 32 dbSNP
rs1462439135 34 dbSNP
rs201937693 35 dbSNP
rs758150043 37 dbSNP
rs371130451 38 dbSNP
rs1168828171 39 dbSNP
rs756569872 40 dbSNP
rs1409223430 41 dbSNP
rs1015897163 43 dbSNP
rs766141270 43 dbSNP
rs375653873 45 dbSNP
rs990519804 52 dbSNP
rs1364100736 56 dbSNP
rs1241444633 58 dbSNP
rs2531 59 dbSNP
rs540730822 64 dbSNP
rs1294930306 65 dbSNP
rs1433367946 67 dbSNP
rs895247433 72 dbSNP
rs865946250 73 dbSNP
rs1466021617 77 dbSNP
rs1022441650 81 dbSNP
rs1170635842 85 dbSNP
rs1450151580 86 dbSNP
rs1474369753 90 dbSNP
rs555550158 91 dbSNP
rs1186834640 101 dbSNP
rs1418677935 102 dbSNP
rs978399323 105 dbSNP
rs1425362598 107 dbSNP
rs1463064142 115 dbSNP
rs1256531694 116 dbSNP
rs923782799 125 dbSNP
rs1276688115 127 dbSNP
rs1345079403 128 dbSNP
rs1019620844 130 dbSNP
rs1340771541 133 dbSNP
rs574204578 135 dbSNP
rs935211665 137 dbSNP
rs1340677655 138 dbSNP
rs780176078 142 dbSNP
rs1395803381 147 dbSNP
rs1377704001 148 dbSNP
rs1310325074 155 dbSNP
rs1430487808 157 dbSNP
rs1291021604 164 dbSNP
rs544802344 180 dbSNP
rs1459687847 184 dbSNP
rs138108626 192 dbSNP
rs117830235 193 dbSNP
rs545668585 198 dbSNP
rs947379214 200 dbSNP
rs1253906725 208 dbSNP
rs143775286 211 dbSNP
rs1182731496 218 dbSNP
rs1248924891 231 dbSNP
rs1293515177 231 dbSNP
rs1336398738 232 dbSNP
rs1356691149 232 dbSNP
rs185547953 239 dbSNP
rs1039469222 244 dbSNP
rs546700312 247 dbSNP
rs907745713 250 dbSNP
rs1320216475 264 dbSNP
rs73313239 268 dbSNP
rs1410921775 274 dbSNP
rs1045529392 275 dbSNP
rs907133067 277 dbSNP
rs1306305760 280 dbSNP
Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions HEK293
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection ...

- Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell.

miRNA-target interactions (Provided by authors)
ID Duplex structure Position
1
miRNA  3' agcugacggugagaAUGAUCu 5'
                        |||||| 
Target 5' ------------ucUACUAGa 3'
1 - 9
Article - Hafner M; Landthaler M; Burger L; Khorshid et al.
- Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
Experimental Support 2 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions HEK293
Disease 6895.0
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... "PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1 ...

- Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods.

miRNA-target interactions (Provided by authors)
ID Duplex structure Position
1
miRNA  3' agcugacggugagaAUGAUCu 5'
                        |||||| 
Target 5' ------------ucUACUAGa 3'
1 - 9
Article - Kishore S; Jaskiewicz L; Burger L; Hausser et al.
- Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
CLIP-seq Support 1 for dataset GSM545216
Method / RBP PAR-CLIP / AGO2
Cell line / Condition HEK293 / miR-124 transfection
Location of target site ENST00000266987.2 | 3UTR | UCUACUAGAGCCUGGAAUAAAUAUGCUGCUUUG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 20371350 / GSE21578
CLIP-seq Viewer Link
CLIP-seq Support 2 for dataset GSM714644
Method / RBP PAR-CLIP / AGO2
Cell line / Condition HEK293 / completeT1, repA
Location of target site ENST00000266987.2 | 3UTR | UCUACUAGAGCCUGGAAUAAAUAUGCUGCUUUG
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 21572407 / GSE28865
CLIP-seq Viewer Link
MiRNA-Target Expression Profile
Dataset Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
GSE19783 ER+ ER+ breast cancer -0.529 8.2e-3 -0.444 2.5e-2 20 Click to see details
GSE21687 Ependynoma primary tumors -0.282 1.2e-2 -0.244 2.6e-2 64 Click to see details
GSE17498 Multiple myeloma -0.343 1.5e-2 -0.372 9.0e-3 40 Click to see details
GSE14794 Lymphoblastoid cells -0.216 2.0e-2 -0.156 7.1e-2 90 Click to see details
GSE32688 Pancreatic cancer 0.348 2.5e-2 0.296 5.0e-2 32 Click to see details
GSE34608 Pulmonary tuberculosis and sarcoidosis -0.403 3.9e-2 -0.537 7.3e-3 20 Click to see details
GSE42095 Differentiated embryonic stem cells -0.374 3.9e-2 -0.379 3.7e-2 23 Click to see details
GSE28544 Breast cancer 0.271 1.0e-1 0.277 9.5e-2 24 Click to see details
GSE19350 CNS germ cell tumors 0.373 1.2e-1 0.399 9.9e-2 12 Click to see details
GSE38974 Chronic obstructive pulmonary disease -0.192 1.8e-1 -0.254 1.1e-1 25 Click to see details
GSE19783 ER- ER- breast cancer 0.102 1.9e-1 0.061 3.0e-1 79 Click to see details
GSE26953 Aortic valvular endothelial cells -0.191 1.9e-1 -0.171 2.1e-1 24 Click to see details
GSE19536 Breast cancer 0.042 3.4e-1 -0.007 4.7e-1 100 Click to see details
GSE17306 Multiple myeloma -0.04 3.9e-1 -0.127 1.9e-1 49 Click to see details
GSE28260 Renal cortex and medulla 0.065 4.2e-1 0.066 4.2e-1 13 Click to see details
GSE27834 Pluripotent stem cells -0.048 4.3e-1 0.112 3.4e-1 16 Click to see details
GSE38226 Liver fibrosis 0.015 4.7e-1 0.125 2.9e-1 21 Click to see details
GSE21849 B cell lymphoma 0.004 4.9e-1 -0.084 3.3e-1 29 Click to see details
GSE21849 B cell lymphoma 0.004 4.9e-1 -0.084 3.3e-1 29 Click to see details
GSE21849 B cell lymphoma 0.004 4.9e-1 -0.084 3.3e-1 29 Click to see details
MiRNA-Target Expression Profile (TCGA)
Tumor Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
STAD 0.393 0.02 0.403 0.02 28 Click to see details
HNSC -0.351 0.02 -0.297 0.04 35 Click to see details
LUAD 0.584 0.04 0.527 0.06 10 Click to see details
BLCA 0.421 0.05 0.419 0.05 17 Click to see details
ESCA 0.516 0.05 0.518 0.05 11 Click to see details
PRAD 0.229 0.09 0.357 0.02 36 Click to see details
CESC 0.95 0.1 1.000 0.5 3 Click to see details
LUSC 0.196 0.13 0.190 0.14 35 Click to see details
UCEC 0.226 0.18 0.193 0.22 18 Click to see details
PCPG 0.828 0.19 0.500 0.33 3 Click to see details
BRCA 0.08 0.33 0.055 0.38 34 Click to see details
KIRP -0.069 0.36 0.015 0.47 29 Click to see details
KICH -0.065 0.39 -0.059 0.4 22 Click to see details
CHOL -0.126 0.39 0.357 0.22 7 Click to see details
THCA -0.033 0.4 -0.038 0.39 58 Click to see details
LIHC 0.035 0.41 0.013 0.46 49 Click to see details
KIRC -0.026 0.44 0.021 0.45 40 Click to see details
PAAD -0.03 0.49 0.200 0.4 4 Click to see details
PAAD -0.03 0.49 0.200 0.4 4 Click to see details
27 hsa-miR-628-3p Target Genes:
Functional analysis:
ID Target Description Validation methods
Strong evidence Less strong evidence
MIRT039584 CDC14A cell division cycle 14A 1 1
MIRT039585 AGO1 argonaute 1, RISC catalytic component 2 3
MIRT039586 TGFBRAP1 transforming growth factor beta receptor associated protein 1 1 1
MIRT039587 LRP6 LDL receptor related protein 6 1 1
MIRT071876 BTF3L4 basic transcription factor 3 like 4 2 2
MIRT097443 JMY junction mediating and regulatory protein, p53 cofactor 2 4
MIRT100100 ABT1 activator of basal transcription 1 2 8
MIRT147692 CBX4 chromobox 4 2 2
MIRT408248 PURA purine rich element binding protein A 2 2
MIRT442047 LRAT lecithin retinol acyltransferase 2 2
MIRT444412 RAB3IP RAB3A interacting protein 2 2
MIRT452599 REPIN1 replication initiator 1 2 2
MIRT469515 RBFOX2 RNA binding protein, fox-1 homolog 2 2 8
MIRT498192 AKR1B10 aldo-keto reductase family 1 member B10 2 2
MIRT500151 CREBBP CREB binding protein 2 2
MIRT507319 FAM60A SIN3-HDAC complex associated factor 2 6
MIRT508343 ZNF273 zinc finger protein 273 2 6
MIRT520480 TRIM13 tripartite motif containing 13 2 2
MIRT522461 MMP16 matrix metallopeptidase 16 2 4
MIRT547116 PHLPP2 PH domain and leucine rich repeat protein phosphatase 2 2 2
MIRT548675 CRNKL1 crooked neck pre-mRNA splicing factor 1 2 2
MIRT553756 TARBP2 TARBP2, RISC loading complex RNA binding subunit 2 4
MIRT559437 ARSJ arylsulfatase family member J 2 2
MIRT610490 GPC4 glypican 4 2 2
MIRT644682 TMCO1 transmembrane and coiled-coil domains 1 2 2
MIRT658214 FBXO21 F-box protein 21 2 2
MIRT756083 TP53 tumor protein p53 4 1
miRNA-Drug Resistance Associations
miRNA Drug Name CID NSC FDA Effect/Pattern Detection Method Level Phenotype Condition
hsa-mir-628 Cisplatin 5460033 NSC119875 approved sensitive cell line (BxPC3)
hsa-miR-628-3p Cisplatin 5460033 NSC119875 approved resistant High Tongue Squamous Cell Carcinoma cell line (Tca8113)
hsa-miR-628-3p Tamoxifen 2733525 NSC180973 approved resistant High Breast Cancer cell line (MCF-7, LY2)
hsa-miR-628-3p Erlotinib 176870 NSC718781 approved sensitive High Epithelial Cancer cell line (A549, UKY-29, H460, H1975, H1650, H3255, PC-9, H358)
hsa-miR-628-3p Siop Treatment Protocol sensitive High Nephroblastoma tissue
hsa-miR-628-3p Sunitinib 5329102 NSC750690 approved resistant High Metastatic Renal Cell Carcinoma tissue and cell line (Caki-2)
hsa-miR-628-3p Chemotherapy sensitive High Epithelial Ovarian Cancer tissue
hsa-miR-628-3p Platinum-based doublet chemotherapy resistant Low Lung Adenocarcinoma tissue
hsa-miR-628-3p Doxorubicin 31703 NSC123127 approved sensitive High Gastric Cancer cell line (SGC7901)
hsa-miR-628-3p Tamoxifen 2733525 NSC180973 approved resistant High Breast Cancer cell line (TAMR8)
hsa-miR-628-3p Aromatase Inhibitor sensitive Low Breast Cancer cell line (MCF-7)
hsa-miR-628-3p Dabrafenib 44462760 NSC764134 approved resistant High Melanoma cell line (A375, IGR37, 501Mel)
hsa-miR-628-3p Vemurafenib 42611257 NSC761431 approved resistant High Melanoma cell line (A375, IGR37, 501Mel)
hsa-miR-628-3p Ceritinib 57379345 NSC776422 approved sensitive High Non-Small Cell Lung Cancer cell line (H3122, H2228)
hsa-miR-628-3p Platinum 23939 sensitive High High-Grade Serous Ovarian Cancer tissue
hsa-miR-628-3p Cisplatin 5460033 NSC119875 approved sensitive High Bladder Cancer cell line (CDDP-R-BOY, CDDP-R-T24)
hsa-miR-628-3p Gefitinib 123631 NSC715055 approved resistant cell line (HCC827)
hsa-miR-628-3p Gefitinib 123631 NSC715055 approved sensitive cell line (HCC827)
hsa-miR-628-3p Fluorouracil 3385 NSC19893 approved resistant cell line (KM12C) (72 h)
hsa-miR-628-3p Sunitinib 5329102 NSC750690 approved resistant tissue (CardB)
hsa-miR-628-3p Tamoxifen 2733525 NSC180973 approved resistant cell line (TamR8)
hsa-miR-628-3p Oxaliplatin 6857599 NSC266046 approved sensitive cell line (IGROV-1)
hsa-miR-628-3p Cisplatin 5460033 NSC119875 approved sensitive cell line (A549)
hsa-miR-628-3p Gemcitabine 60750 NSC613327 approved sensitive cell line (PANC-1) (1500 ng/ml)
hsa-miR-628-3p Docetaxel+Cisplatin+5-Fluorouracil sensitive tissue (hypopharyngeal squamous cell carcinoma)

Error report submission